Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Philippe Foy

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Oncotarget|June 10, 2016
MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinomaNathalie Bonnin, Emma Armandy, Julien Carras, et al.
Oncotarget|March 31, 2016
The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancerJean-Philippe Foy, Antonin Tortereau, Carlos Caulin, et al.
Journal of the National Cancer Institute|April 5, 2018
Met Receptor Tyrosine Kinase and Chemoprevention of Oral CancerPierre Saintigny, William N William, Jean-Philippe Foy, et al.
Iscience|May 26, 2020
CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell PlasticityMaha Siouda, Audrey D Dujardin, Laetitia Barbollat-Boutrand, et al.
Oncoimmunology|December 8, 2018
Immunological and classical subtypes of oral premalignant lesionsJean-Philippe Foy, Chloé Bertolus, Sandra Ortiz-Cuaran, et al.
Cancer Research Communications|September 14, 2023
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many CancersBoris Guyot, Flora Clément, Youenn Drouet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2022
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patientsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Data in Brief|September 16, 2022
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitorsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2015
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2022
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancerSandra Ortiz-Cuaran, Aurélie Swalduz, Jean-Philippe Foy, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Oncotarget|June 10, 2016
MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinomaNathalie Bonnin, Emma Armandy, Julien Carras, et al.
Oncotarget|March 31, 2016
The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancerJean-Philippe Foy, Antonin Tortereau, Carlos Caulin, et al.
Journal of the National Cancer Institute|April 5, 2018
Met Receptor Tyrosine Kinase and Chemoprevention of Oral CancerPierre Saintigny, William N William, Jean-Philippe Foy, et al.
Iscience|May 26, 2020
CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell PlasticityMaha Siouda, Audrey D Dujardin, Laetitia Barbollat-Boutrand, et al.
Oncoimmunology|December 8, 2018
Immunological and classical subtypes of oral premalignant lesionsJean-Philippe Foy, Chloé Bertolus, Sandra Ortiz-Cuaran, et al.
Cancer Research Communications|September 14, 2023
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many CancersBoris Guyot, Flora Clément, Youenn Drouet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2022
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patientsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Data in Brief|September 16, 2022
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitorsJean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2015
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2022
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancerSandra Ortiz-Cuaran, Aurélie Swalduz, Jean-Philippe Foy, et al.
Pageof 5